Home › NCT07697625

A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)

A Clinical Study to Evaluate the Plasma Pharmacokinetics of a Single Dose of MK-4082 With and Without Diltiazem Coadministration in Healthy Participants

Who can join

Ages 18 to 55 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Is in good health
* Body mass index (BMI) between 18 and 32 kg/m\^2, inclusive

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has a history of previous surgical treatment for obesity that may induce malabsorption, history of bowel resection \>20 cm, any malabsorption disorder, severe gastroparesis, or any GI procedure for weight loss
* Had a recent pancreatitis or has a history of pancreatitis

About the study

Researchers are looking for new weight loss medicines for people with higher body weight. The trial medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a trial medicine to participants with a health condition, researchers first do trials in healthy participants to find a safe dose level (amount) of the trial medicine.

The goal of this study is to learn what happens to MK-4082 in a person's body over time. Researchers will compare what happens to levels of MK-4082 in people's blood when it is taken alone (Part 1, Period 1 and Part 2) and in combination with (Part 1, Period 2) another medicine called diltiazem. Researchers also want to learn about the safety of MK-4082 taken with and without diltiazem and if people tolerate them.

What is being tested

• MK-4082 (drug)
• Diltiazem (drug)
• Rescue medication (drug)

Sponsor: Merck Sharp & Dohme LLC · Participants: 28 · Started: Jul 20, 2026

Contact the study team

• Toll Free Number · Phone: 1-888-577-8839

Official record on ClinicalTrials.gov — NCT07697625

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.